Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179751 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas
A Phase 1 study, sponsored by Celgene Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00179751: Clinical Trial Phase 1 study, sponsored by Celgene Corporation.
NCT00179751 is a Phase 1 study that was terminated before completion, run by Celgene Corporation. The registered enrollment target is 50 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00179751, a Phase 1 study, was terminated before completion, sponsored by Celgene Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Phase I will determine the MDT and evaluate the safety profile of oral lenalidomide days 1-21 and weekly gemcitabine days 1, 8, \& 15 in 28 day cycles Phase II will explore the anti-tumor activity and safety of the combination in subjects with advanced pancreatic carcinoma. Subjects will receive oral lenalidomide days 1-21 and weekly gemcitabine days 1, 8, \& 15 in 28 day cycles until documented disease progression occurs.
Interventions
- DRUG gemcitabine
- DRUG CC-5013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Why NCT00179751 stopped before completion
NCT00179751 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 2 interventions - of which gemcitabine is the first listed.
NCT00179751 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00179751 about?
NCT00179751 is a clinical study titled "A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas". Phase I will determine the MDT and evaluate the safety profile of oral lenalidomide days 1-21 and weekly gemcitabine days 1, 8, \& 15 in 28 day cycles Phase II will explore the anti-tumor activity and safety of the combination in subjects with advanced pancreatic carcinoma. Subjects will receive ora...
What is the current status of trial NCT00179751?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2005-04. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00179751?
The interventions under investigation include: gemcitabine (DRUG), CC-5013 (DRUG).
Who is sponsoring clinical trial NCT00179751?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00179751's enrollment target sits among peer trials
50 973rd of 2000 higher than 984 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia